Viewing Study NCT01266603

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:25 PM
Ignite Modification Date: 2026-01-27 @ 10:50 AM
Study NCT ID: NCT01266603
Status: COMPLETED
Last Update Posted: 2020-02-19
First Post: 2010-12-20
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
Sponsor: M.D. Anderson Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Melanoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Metastatic Melanoma View
None Unresectable Melanoma View
None HDIL-2 View
None Interleukin-2 View
None IL-2 View
None Aldesleukin View
None Proleukin View
None recMAGE-A3 + AS15 View
None ASCI View
None recMAGE-A3 View
None Recombinant MAGE-A3 protein View
None recMAGE-A3 + AS15 ASCI View
None MAGE-A3 View
None MAGE-A3 ASCI View